A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.

Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- ...

A new nanozyme-antibody platform selectively targets HER2-positive tumors, disrupting gene expression and reducing metastasis ...

In 2022, there were 2.3 million women diagnosed with breast cancer and 670,000 deaths worldwide, according to the World ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory (LLNL), BBOT (BridgeBio Oncology Therapeutics ...

Pathway analysis identified elevated EMT and WNT-beta catenin signaling and absence of ERBB2 gene amplification and HER2 protein overexpression associated with cases not responding to treatment.

Pathway analysis identified elevated EMT and WNT-beta catenin signaling and absence of ERBB2 gene amplification and HER2 protein overexpression associated with cases not responding to treatment.

AbstractIntroduction:. Persistent activation of the EGFR/K-RAS pathway is a major driver of tumor malignancy. Therapies attempting to contravene intertwined RAS effector pathways have yet to achieve ...

The authors discuss several major pathways involved in breast cancer, including PI3K/Akt/mTOR, RAS/RAF/MEK/ERK, HER2, Wnt/β-catenin, Notch, NF-κB, and the DNA damage response (DDR). These ...

BUFFALO, NY - March 25, 2025 – A new review was published in Oncotarget, Volume 16, on March 13, 2025, titled “Signaling pathway dysregulation in breast cancer." ...